Korro Bio (KRRO) Common Equity (2018 - 2026)

Korro Bio (KRRO) has reported Common Equity for 9 consecutive years, with $103.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 10.32% year-over-year to $103.2 million; the trailing twelve-month figure through Jun 2026 stood at $103.2 million (down 10.32% YoY), and the FY2025 full-year result was $51.4 million, down 67.93% from the prior year.
• Common Equity declined to $103.2 million in Q2 2026 per KRRO's latest filing, from $119.6 million in the prior quarter.
• Across five years, Common Equity topped out at $198.1 million in Q2 2024 and bottomed at -$153.3 million in Q3 2023.
• Historically, Common Equity has averaged $70.6 million across 5 years, with a median of $107.9 million in 2022.
• The widest YoY moves for Common Equity: up 271.57% in 2023, down 286.96% in 2023.
• Over 5 years, Common Equity stood at -$99.0 million in 2022, then surged by 271.57% to $169.9 million in 2023, then retreated by 5.59% to $160.4 million in 2024, then plunged by 67.93% to $51.4 million in 2025, then jumped by 100.68% to $103.2 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $103.2 million, $119.6 million, and $51.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.